A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics

Author(s): Nilesh Kumar Sharma*

Journal Name: Current Cancer Therapy Reviews

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer
Call for Editor


In recent, curiosity is at the forefront to understand the complexity of cancer driven by genetic, molecular and epigenetic programming due to life style, environmental pressure and metabolite adaptations. On the other hand, complex and heterogeneous nature of cancer is linked to the metabolic and molecular landscape of diabetic complications. This Letter to editor connects the dots and highlights the need to view cancer beyond the mirror of genetic and epigenetic aberration as metabolic disturbances. In this commentary, the author highlights the major contributions from two elegant papers from Cha et al. (2018) and Wu et al. (2018) by delineating molecular pathways that lead to the potential use of anti-diabetic drug metformin and other potential repurposing drugs towards cancer therapeutics.

Keywords: Aging, diabetes, tumor, cancer, epigenetic programming, metabolite.

Prasad NK. Two diseases with one hit: Inhibiting a potential diabetes target to reduce cancer risk and to improve anti-cancer therapy. Curr Cancer Ther Rev 2009; 5(2): 111-21.
Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011; 7(6): 727-36.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013; 13: 235.
Salis O, Bedir A, Ozdemir T, Okuyucu A, Alacam H. The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line. Eur Rev Med Pharmacol Sci 2014; 18(11): 1602-9.
Cha JH, Yang WH, Xia W, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell 2018; 71(4): 606-20.e7.
Golias T, Kery M, Radenkovic S, Papandreou I. Microenviron-mental control of glucose metabolism in tumors by regulation of pyruvate dehydrogenase. Int J Cancer 2018; 144(4): 674-86.
Restifo D. Williams JS2, Garacci E, Walker RJ, Ozieh MN, Egede LE. Differential relationship between colorectal cancer and diabetes in a nationally representative sample of adults. J Diabetes Complications 2018; 32(9): 819-23.
Wu D, Hu D, Chen H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature 2018; 559(7715): 637-41.
Seliger C, Luber C, Gerken M, Schaertl J, Proescholdt M. Use of metformin and survival of patients with high-grade glioma. Int J Cancer 2018; 144(2): 273-80.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [170 - 171]
Pages: 2
DOI: 10.2174/1573394714666181022123329

Article Metrics

PDF: 23
PRC: 1